BioSyent, Inc. (RX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Knight Therapeutics, Inc.

Fennec Pharmaceuticals, Inc.

BioSyent, Inc.

HLS Therapeutics, Inc.

InnoCan Pharma Corp.

Ayr Wellness, Inc.

NervGen Pharma Corp.

Defence Therapeutics Inc

Arch Biopartners, Inc.

Cybin, Inc.

Mindset Pharma, Inc.

Why is BioSyent, Inc. ?

High Management Efficiency with a high ROE of 18.15%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 7.50

Flat results in Mar 26

INTEREST(HY) At CAD 0.04 MM has Grown at 59.17%
INTEREST COVERAGE RATIO(Q) Lowest at 11,587.78
RAW MATERIAL COST(Y) Grown by 6.05% (YoY)

With ROE of 21.64%, it has a fair valuation with a 4.45 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 14.64%, its profits have risen by 21.4% ; the PEG ratio of the company is 0.9

Underperformed the market in the last 1 year

The stock has generated a return of 14.64% in the last 1 year, much lower than market (S&P/TSX 60) returns of 28.43%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to BioSyent, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is BioSyent, Inc. for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

BioSyent, Inc.

19.85%

7.05

29.14%

S&P/TSX 60

29.6%

2.24

12.72%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

14.18%

EBIT Growth (5y)

15.56%

EBIT to Interest (avg)

7.50

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.48

Sales to Capital Employed (avg)

0.98

Tax Ratio

25.74%

Dividend Payout Ratio

25.62%

Pledged Shares

Institutional Holding

ROCE (avg)

100.69%

ROE (avg)

18.15%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.59

EV to EBIT

13.45

EV to EBITDA

12.25

EV to Capital Employed

4.03

EV to Sales

3.38

PEG Ratio

1.14

Dividend Yield

ROCE (Latest)

29.95%

ROE (Latest)

20.09%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CAD 12.17 MM

DIVIDEND PER SHARE(HY)

Highest at CAD 7.06

NET SALES(Q)

Highest at CAD 13.91 MM

OPERATING PROFIT(Q)

Highest at CAD 3.66 MM

-14What is not working for the Company

INTEREST(HY)

At CAD 0.04 MM has Grown at 59.17%

INTEREST COVERAGE RATIO(Q)

Lowest at 11,587.78

RAW MATERIAL COST(Y)

Grown by 6.05% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -12.56 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 7.06 times

OPERATING PROFIT MARGIN(Q)

Lowest at 26.34 %

Here's what is working for BioSyent, Inc.

Operating Cash Flow

Highest at CAD 12.17 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CAD MM)

Net Sales

Highest at CAD 13.91 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Net Sales

At CAD 13.91 MM has Grown at 29.22%

over average net sales of the previous four periods of CAD 10.76 MM

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Operating Profit

Highest at CAD 3.66 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CAD MM)

Dividend per share

Highest at CAD 7.06

in the last five years

MOJO Watch

Company is distributing higher dividend from profits generated

DPS (CAD)

Here's what is not working for BioSyent, Inc.

Interest

At CAD 0.04 MM has Grown at 59.17%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)

Interest Coverage Ratio

Lowest at 11,587.78

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Operating Profit Margin

Lowest at 26.34 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Debt-Equity Ratio

Highest at -12.56 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 7.06 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 6.05% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales